We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Task Force Urges Sweeping Reforms To Bolster Indian Device Sector

Task Force Urges Sweeping Reforms To Bolster Indian Device Sector

April 17, 2015

A public-private task force in India is urging the government to purchase Indian-made medical devices when possible to boost growth in the domestic medtech industry.

To support newer companies, the Task Force on the Medical Devices Sector in India also recommends that the government relax rules encouraging only firms that have been in business for at least three to five years to bid on government contracts. Preference also should be given to devices made by smaller companies, says a report released by the group this week.

Pricing for devices should be regulated separately from drugs and would be based more strongly on return on investment for manufacturers, the task force suggests. This would allow the government to consider the costs of a complete “basket” of devices associated with a single procedure, a move that would help to keep the industry viable. The group also calls for tax and duty reforms, including discounts on import duties, restrictions on the import of secondhand diagnostic tools and promotion of medical device exports.

These new policies should be supported by an independent facilitating body devoted to the medical device sector, the report says. This body would create benchmarks based on international best practices, develop public-private knowledge networks, and identify and prevent technical barriers to trade. In addition, the Department of Pharmaceuticals should be strengthened and renamed the Department of Pharmaceuticals and Medical Devices, the task force advises.

The report also calls for the government to build infrastructure to support medical device parks with common medical device testing facilities that would be funded at least partially by industry. One such park is already planned for Chennai.

To speed technological upgrades, the government should create a system that would allow device companies to exchange intellectual property, the task force adds. Incubation centers should be established and more government seed money provided for start-ups, the group adds.

Part of Make in India

The secretary of the Department of Pharmaceuticals established the task force last fall to bolster Prime Minister Narendra Modi’s Make in India campaign. The group sought input from government, industry and consulting groups before issuing its recommendations.

Rajiv Nath, forum coordinator of device industry group AIMED praised the task force’s report. “It sets a clear and definite road map for creation of a vibrant ecosystem for manufacturing of medical devices in the country,” he tells IDDM. If the recommendations are implemented quickly and thoroughly, they could allow India to end its dependence on device imports in just a few years, he adds.

Recommendations concerning financial support to manufacturing units, reversal of inverted duty structure, an MRP-based taxation system, creation of a separate department and separate law book for medical devices were of particular significance, Nath says. Still, additional measures — such as higher duties on imported finished goods — may be needed to fully encourage the sector, he adds.

View the report at www.fdanews.com/04-20-15-taskforce.pdf. — Elizabeth Orr

Regulatory Affairs

Upcoming Events

  • 10Mar

    FDA Drug GMP Facility Inspections During the Pandemic

  • 16Mar

    Pharmaceutical Naming Regulation: Understanding the Latest Developments

  • 18Mar

    Pharmaceutical Postmarket Surveillance: Latest Developments in the Era of COVID-19

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 30Mar

    Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

  • 06Apr

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • FDA clears text

    Vetex Medical’s Thrombectomy Catheter Cleared by FDA

  • 100Bills_flatmoney.gif

    Merck Purchases Rights to Debiopharm’s Xevinapant for More Than $1 Billion

  • abbott-logo.gif

    Abbott Gets FDA EUA for COVID-19 IgG Antibody Test

  • 100Bills_flatmoney.gif

    In $1.55 Billion Deal, Perrigo Sells Off Generic Drug Business

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing